A multicenter, randomized, double blind, placebo-controlled clinical trial of DL-3-n-butylphthalide in treatment of amyotrophic lateral sclerosis
Main Authors: | Mingsheng Liu, Xiaoli Yao, Xusheng Huang, Huifang Shang, Dongsheng Fan, Jia He, Liying Cui, the Chinese ALS Study Group, Jinjiao Li, Yuanyuan Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2023-02-01
|
Series: | Chinese Medical Journal |
Online Access: | http://journals.lww.com/10.1097/CM9.0000000000002442 |
Similar Items
-
The neuroprotective effect of Dl-3-n-butylphthalide in epileptic rats via inhibiting endoplasmic reticulum stress
by: Shuang Tian, et al.
Published: (2023-01-01) -
Effect of Dl-3-n-Butylphthalide on olfaction in rotenone-induced Parkinson’s rats
by: Jiawei Wang, et al.
Published: (2024-04-01) -
Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
by: Jessica Mandrioli, et al.
Published: (2023-08-01) -
Effect of Dl-3-n-butylphthalide on mitochondrial Cox7c in models of cerebral ischemia/reperfusion injury
by: Jingjing Jia, et al.
Published: (2023-02-01) -
DL-3-n-butylphthalide (NBP) alleviates poststroke cognitive impairment (PSCI) by suppressing neuroinflammation and oxidative stress
by: Hui Zhang, et al.
Published: (2023-01-01)